LivaNova/$LIVN
1D1W1MYTD1Y5YMAX
Capital at risk
About LivaNova
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
- Ticker
- $LIVN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,300
- Headquarters
- Gloucester, United Kingdom
- Website
- www.livanova.com
LivaNova Metrics
BasicAdvanced
$4.1B
21.96
$3.40
0.87
-
Price and volume
Market cap
$4.1B
Beta
0.87
52-week high
$85.76
52-week low
$48.82
Average daily volume
646K
Financial strength
Current ratio
1.45
Quick ratio
1.058
Long term debt to equity
0.256
Total debt to equity
0.266
Interest coverage (TTM)
6.07%
Profitability
EBITDA (TTM)
262.325
Gross margin (TTM)
67.74%
Net profit margin (TTM)
12.82%
Operating margin (TTM)
14.10%
Effective tax rate (TTM)
-76.97%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
5.04%
Return on equity (TTM)
15.40%
Valuation
Price to earnings (TTM)
21.958
Price to revenue (TTM)
2.777
Price to book
3.1
Price to tangible book (TTM)
12.49
Price to free cash flow (TTM)
27.558
Free cash flow yield (TTM)
3.63%
Free cash flow per share (TTM)
2.711
Growth
Revenue change (TTM)
12.39%
Earnings per share change (TTM)
-187.47%
3-year revenue growth (CAGR)
10.70%
3-year earnings per share growth (CAGR)
23.36%
What the Analysts think about LivaNova
Analyst ratings (Buy, Hold, Sell) for LivaNova stock.
Analyst projections of the future price of LivaNova stock.
Bulls say / Bears say
Second-quarter constant-currency revenue rose 9.8%, with both Cardiopulmonary and Neuromodulation growing. LivaNova raised its 2026 revenue growth and adjusted EPS outlook, signalling confidence in its core businesses. (Morningstar)
A long-term Thermo Fisher supply agreement is expected to ease a shortage of a key oxygenator component and allow higher output over time. That could help LivaNova meet unmet demand and sustain growth in Cardiopulmonary. (Morningstar)
New PolySync data showed an 84.5% response rate in patients with moderate-to-severe obstructive sleep apnoea. Better outcomes could strengthen the case for LivaNova’s stimulation therapy and widen its growth opportunity in this market. (Morningstar)
Despite raising revenue and adjusted EPS guidance, LivaNova cut its 2026 adjusted free cash flow forecast to $140–160 million from $160–180 million. Higher spending on capacity, innovation and IT may therefore limit near-term cash generation. (Morningstar)
Second-quarter adjusted EPS benefited from a $6 million tariff refund, worth about $0.08 per share, which management does not expect to recur. This makes the reported earnings increase less representative of the ongoing run rate. (The Motley Fool)
LivaNova still carries a €337.8 million ($385 million) SNIA environmental liability, and the related proceedings remain ongoing, with another hearing scheduled for December 2026. The unresolved case leaves a material legal and financial overhang. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2026.
LivaNova Financial Performance
Revenues and expenses
LivaNova Earnings Performance
Company profitability
Upcoming events
No upcoming events
LivaNova News
AllArticlesVideos
Funds containing LivaNova
AllUSDEURGBP
Fund name | Fund size | $LIVN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.42% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.42% |
iShares Healthcare Innovation£DRDR | £1B | 0.42% |
iShares Ageing Population€AGED | €822M | 0.37% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.